Pomerantz Law Firm Initiates Class Action Against Inovio Pharmaceuticals Over Securities Violations

Overview

Pomerantz LLP has officially filed a class action lawsuit against Inovio Pharmaceuticals, Inc. and certain officials associated with the company. This lawsuit, which cites violations of federal securities laws, is currently pending in the United States District Court for the Eastern District of Pennsylvania. The class action represents all individuals and entities, excluding the defendants, who bought or acquired Inovio securities during the specified class period from October 10, 2023, to December 26, 2025.

Details of the Case

The crux of the lawsuit revolves around allegations that Inovio and its executives misled investors about the company’s performance and the timeline regarding an essential product. Specifically, the plaintiffs seek damages under Section 10(b) and 20(a) of the Securities Exchange Act of 1934, as well as Rule 10b-5, which prohibits deceit in connection with the purchase or sale of securities.

Individuals who purchased Inovio securities within the specified time frame have until April 7, 2026, to opt to be appointed as Lead Plaintiff in this case. A copy of the formal complaint can be obtained via Pomerantz’s website, which also provides a dedicated contact line for inquiries.

Background on Inovio Pharmaceuticals

Inovio Pharmaceuticals specializes in biotechnology with a particular focus on developing DNA medicines to combat diseases, including those related to human papillomavirus (HPV). Central to their operations is a proprietary investigational medical device, CELLECTRA, which facilitates the cellular uptake of their DNA medicines. Their lead product candidate, INO-3107, targets recurrent respiratory papillomatosis (RRP), a persistent condition caused by HPV.

Over the class period, Inovio executives frequently assured investors that they were on track for FDA approval of INO-3107. These optimistic projections suggested that the product was approaching market readiness, potentially revolutionizing treatments for conditions caused by HPV. The executives maintained that they would be able to submit the biologics license application (BLA) by the latter half of 2024. This assertion was a critical element of the investment case.

Misleading Statements and Financial Impact

Despite these claims, the lawsuit alleges that the company and its executives disseminated materially false and misleading information about its business health. Specific allegations include undetected deficiencies in the manufacturing of CELLECTRA, leading to delays in BLA submission, as well as an overall lack of substantial justification for their previous claims around FDA accelerated approval. Consequently, the lawsuit argues that the public statements made by the defendants were persistently misleading.

The first signs of trouble emerged on August 8, 2024, when Inovio announced delays related to the INO-3107 BLA, resulting in a significant drop in their stock price. Subsequently, on December 29, 2025, the FDA’s acceptance of the BLA on a standard review basis—rather than an expedited process—triggered an even larger decline in Inovio's stock price.

Conclusion and Next Steps

The ramifications of these legal proceedings for Inovio Pharmaceuticals and its investors remain to be seen. With Pomerantz LLP recognized as a leading player in securities class action litigation, they continue to advocate for the rights of investors affected by corporate misconduct. As the court proceedings unfold, investors who believe they have been impacted by these alleged violations are encouraged to review their options for participating in the class action.

For ongoing updates, investors can follow Pomerantz’s official communications or consult directly with their legal representatives.

Contact Information

For further inquiries or to discuss the action, interested parties can reach out to:
Danielle Peyton at Pomerantz LLP
Email: [email protected]
Phone: 646-581-9980 (toll-free at 888.4-POMLAW)

About Pomerantz LLP

Pomerantz LLP has a long-standing reputation in corporate, securities, and antitrust litigation, recovering billions of dollars for class members over its 85-year history. The firm was established by Abraham L. Pomerantz, regarded as a pioneer in securities class actions, and continues to uphold its founding principles by fighting for victims of corporate wrongdoing.